OKYO Pharma (OKYO) Cash & Equivalents (2021 - 2025)

OKYO Pharma (OKYO) has 5 years of Cash & Equivalents data on file, last reported at $4.2 million in Q3 2025.

• Cash & Equivalents for Q3 2025 came in at $4.2 million, up 410.42% year-over-year; the trailing twelve-month figure through Sep 2025 was $4.2 million (up 410.42% YoY), and the FY2025 annual result was $826848.0, changed 0.0% from the prior year.
• Cash & Equivalents advanced to $4.2 million in Q3 2025 per OKYO's latest filing, from $826848.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $6.9 million in Q1 2021 and troughed at $826848.0 in Q1 2024.
• A 5-year average of $3.0 million and a median of $3.4 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents sank 79.56% in 2024, then surged 410.42% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $6.9 million in 2021, then sank by 60.8% to $2.7 million in 2022, then jumped by 49.79% to $4.0 million in 2023, then slumped by 79.56% to $826848.0 in 2024, then surged by 410.42% to $4.2 million in 2025.
• Business Quant data shows OKYO's Cash & Equivalents at $4.2 million in Q3 2025, $826848.0 in Q1 2025, and $826848.0 in Q3 2024.